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Abstract
Colorectal liver metastases (CRLM) exhibit distinct histopathological growth patterns (HGPs) that are indicative of prog-
nosis following surgical treatment. This study aims to assess the reliability and replicability of this histological biomarker. 
Within and between metastasis HGP concordance was analysed in patients who underwent surgery for CRLM. An inde-
pendent cohort was used for external validation. Within metastasis concordance was assessed in CRLM with ≥ 2 tissue 
blocks. Similarly, concordance amongst multiple metastases was determined in patients with ≥ 2 resected CRLM. Diagnostic 
accuracy [expressed in area under the curve (AUC)] was compared by number of blocks and number of metastases scored. 
Interobserver agreement (Cohen’s k) compared to the gold standard was determined for a pathologist and a PhD candidate 
without experience in HGP assessment after one and two training sessions. Both the within (95%, n = 825) and the between 
metastasis (90%, n = 363) HGP concordance was high. These results could be replicated in the external validation cohort with 
a within and between metastasis concordance of 97% and 94%, respectively. Diagnostic accuracy improved when scoring 
2 versus 1 blocks(s) or CRLM (AUC = 95.9 vs. 97.7 [p = 0.039] and AUC = 96.5 vs. 93.3 [p = 0.026], respectively), but not 
when scoring 3 versus 2 blocks or CRLM (both p > 0.2). After two training sessions the interobserver agreement for both 
the pathologist and the PhD candidate were excellent (k = 0.953 and k = 0.951, respectively). The histopathological growth 
patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy, 
making them a reliable and replicable histological biomarker.
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Introduction
Colorectal cancer (CRC) is one of the most prevalent solid 
malignancies in the world with approximately one third of 
patients developing hepatic metastases [1–5]. Even though 
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surgical treatment is seen as the only potentially curative 
treatment option, reported 5-year survival rates vary widely 
(from 20 to 70%) [6–13].
Recently, a new potential histological biomarker has been 
described [14, 15]. Colorectal liver metastases (CRLM) 
grow in three distinct histopathological growth patterns 
(HGP), the desmoplastic, the replacement and the push-
ing type, each with unique morphological and biological 
features (Fig. 1a–f). These distinct features have previously 
been described in detail [16–18]. In short: HGP assessment 
is performed by assessing the proportion (expressed as per-
centage) of each distinct HGP observed at the tumour-liver 
interface on H&E stained tissue sections [14]. Previous stud-
ies suggest that a high relative proportion of the replacement 
type is prognostic for an impaired overall survival [19–22]. 
The largest and most recent study analysed a cohort of 732 
patients and found that it is the presence rather than the 
relative proportion of any non-desmoplastic type HGP (i.e. 
pushing and/or replacement type) that dictates poor progno-
sis [15]. In terms of clinical relevance, HGPs can therefore 
be classified into two categories: either pure desmoplastic 
(dHGP) or any observed non-desmoplastic type HGP (non-
dHGP) [15].
While interesting from a biological point of view, this 
new classification raises methodological concerns. For 
if classification is based on either 100% dHGP or < 100% 
dHGP, assessment could be more susceptible to sampling 
and reading error. In order to validate HGPs as a histological 
biomarker, knowledge on HGP concordance within a single 
and amongst multiple metastases within the same patient 
is essential, especially considering the growing evidence 
of (non-)genetic intra-tumoural heterogeneity in CRC [23]. 
Knowledge on diagnostic accuracy and learnability of HGP 
assessment is also necessitated to determine the reliability 
and replicability of this histological biomarker. This study 
therefore analyses within and between metastasis HGP con-
cordance within the same cohort as described by Galjart 
et al. [15], as well as an external validation cohort [24]. In 
addition, diagnostic accuracy is determined for scoring a 
single or multiple formalin-fixed paraffin-embedded (FFPE) 
tissue blocks per CRLM and for scoring a single or multiple 
CRLM per patient. Lastly, the learning curve associated with 
HGP assessment is determined in two observers (patholo-
gist and PhD candidate) without prior experience in HGP 
assessment.
Methods
The current study was approved by the medical ethics com-
mittee of the Erasmus University Medical Center (MEC-
2018-1743). The need for informed consent was waived by 
the ethics committee due to the retrospective and non-inva-
sive nature of the study. Drafting of the manuscript was per-
formed in accordance with the REMARK guidelines [25].
Fig. 1  Three distinct types of histopathological growth patterns 
(HGPs) can be identified on H&E stained tissue blocks. a–c × 2.5 
magnification. d–f × 20 magnification. a, d Pushing type HGP. b, e 
Replacement type HGP. c, f Desmoplastic type HGP. T tumour, NL 
normal liver, D desmoplastic stroma
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Patient selection
The patient selection for the current study was performed in 
the same cohort as described by Galjart et al. [15]. Patients 
undergoing resection of CRLM at the Erasmus MC Cancer 
Institute, the Netherlands, between January 2000 and March 
2015 were eligible for inclusion.
Routine pathological assessment
During macroscopic pathological assessment of the surgical 
specimens of resected CRLM, representative sections (e.g. 
tumour, tumour with relation to the surgical margin(s), cap-
sule, background liver, non-tumorous liver in distance) were 
considered for preparation of FFPE tissue blocks. A 5 µm 
section per block was cut and stained with Haematoxylin 
and Eosin (H&E) for pathological interpretation. If needed, 
deeper levels of the block were cut and stained with H&E.
Assessment of HGPs
H&E stained slides retrieved from the archive of the Pathol-
ogy Department of the Erasmus MC were retrospectively 
reviewed by light microscopy (Fig. 1a–f). Scoring of the 
HGPs was performed in accordance with international con-
sensus guidelines [14]. For each block subjected to review 
the relative presence [in percentage (%)] at the tumour-liver 
interface of the distinct HGP’s (pushing, desmoplastic and 
replacement type) was estimated. The metastasis HGP was 
defined as the pooled estimate (average with equal weights 
per block) of all blocks of a single CRLM. Concordantly, 
the patient HGP was defined as the pooled estimate (aver-
age with equal weights per CRLM) of all resected CRLM 
within a single patient. Given recent findings [15], block, 
metastasis and patient HGP were classified as dHGP if only 
the desmoplastic type was observed (i.e. 100% dHGP), and 
as non-dHGP if any percentage of pushing and/or replace-
ment type was observed (i.e. < 100% dHGP). Due to this on/
off classification, if non-dHGP is observed on a single block, 
corresponding metastasis and patient HGP is classified as 
non-dHGP, regardless of the HGP of other blocks within 
the same metastasis or other CRLM within the same patient.
For the within metastasis analysis, concordance (yes/
no) of block HGP to metastasis HGP was recorded for all 
resected CRLM with ≥ 2 tissue blocks. Within metastasis 
concordance was defined as the proportion of concord-
ant tissue blocks. Since a lesion represents a three dimen-
sional structure, consecutive slides from a single block (i.e. 
deeper levels) do not adequately represent its three dimen-
sional nature. As such, consecutive slides from a single 
block were excluded from the within metastasis analysis. 
For the between metastasis analysis, concordance (yes/no) 
of metastasis HGP to patient HGP was determined in all 
patients with ≥ 2 CRLM resected in a single time-frame (e.g. 
no recurrent CRLM). Between metastasis concordance was 
defined as within patient proportion of concordant CRLM. 
Patient information and data on primary CRC and CRLM 
were extracted from a prospectively maintained database. 
Regarding systemic treatment status, patients were consid-
ered chemo-naive if they did not receive any form of chemo-
therapy within the 6 months prior to resection. Multivariable 
logistic regression analysis was performed for within metas-
tasis discordance (yes/no) with primary tumour character-
istics, known clinical risk factors, systemic treatment status 
and number of blocks scored entered into the model. Sig-
nificant predictor(s) found for within metastasis discordance 
were used as stratification factor(s) for between metastasis 
analysis. Identical models were fitted within each stratum (if 
applicable) to predict discordance (yes/no) amongst multi-
ple metastases. Mean within metastasis concordance was 
compared across number of blocks scored. Similarly, mean 
between metastasis concordance was compared within strata 
(if applicable) and by number of CRLM resected.
External validation
External validation of mean within and mean between 
metastasis concordance was performed by retrospective 
HGP assessment as described previously. The external vali-
dation cohort comprised of chemo-naive patients treated 
surgically for CRLM at the University Hospital of Heidel-
berg, Germany, between October 2001 and June 2009 [24]. 
H&E stained sections of the validation cohort were provided 
by the tissue bank of the National Center for Tumor Dis-
eases (NCT). As the external validation cohort consisted of 
chemo-naive patients, comparisons to the original cohort 
were performed in (tissues from) chemo-naive patients only.
Diagnostic accuracy
Diagnostic accuracy for scoring a single FFPE block was 
determined in all CRLM with ≥ 2 blocks. Of these ≥ 2 
blocks, one individual block was selected at random. The 
HGP of this randomly selected block was considered the 
predictor (i.e. test result), while the metastasis HGP—as 
determined by HGP assessment of all ≥ 2 blocks of the 
metastasis in question—was considered the response (i.e. 
true HGP status). This was done similarly for 2 blocks in all 
CRLM with ≥ 3 blocks. Identically, the diagnostic accuracy 
of scoring a single resected CRLM was determined within 
patients with ≥ 2 CRLM resected etc. The area under the 
curve [AUC] of the corresponding receiver operating charac-
teristic (ROC) curves were compared for 2 versus 1 block(s) 
or CRLM scored, and for 3 versus 2 blocks or CRLM scored, 
respectively.
314 Clinical & Experimental Metastasis (2019) 36:311–319
1 3
Learning curve
A gastro-intestinal pathologist (MD) and a PhD-candidate 
(DH) without prior pathology experience were recruited for 
learning curve analysis. Both observers had no prior experi-
ence in HGP assessment. The raters received a joint training 
session by a pathologist with over 10 years of experience in 
HGP assessment (PV). During this training session, 50 tis-
sue sections were assessed collaboratively. Hereafter, both 
observers independently scored a test-set of an additional 
50 tissue sections. Individual scores of the test-set were 
reviewed in a joint session with the trainer, followed by a 
second training session of 50 tissue sections. Subsequently 
a second test-set of 50 tissue sections was scored indepen-
dently. After completion scores were again collaboratively 
reviewed. For both test-sets, interobserver agreement of both 
observers compared to the gold standard was determined 
for the dHGP/non-dHGP classification. The scores of the 
experienced trainer were considered the gold standard.
Statistical analysis
Dichotomous or categorical data are reported as percentage, 
parametric continuous data are reported as mean (standard 
deviation [SD]) and non-parametric continuous data are 
reported as median (inter-quartile range [IQR]). Mean 
concordances were compared by an independent samples 
T test or a one-way analysis of variance (ANOVA), depend-
ing on the number of strata. AUC values were compared 
as described by DeLong [26]. Interobserver agreement was 
determined using Cohen’s kappa. All statistical analyses 
were performed using R version 3.5.3 (http://www.r-proje 
ct.org). The R-package ‘pROC’ was used for comparison of 
AUC values. A p-value < 0.05 was considered statistically 
significant.
Results
Patient characteristics
In total 785 patients underwent resection of one or more 
CRLM at the Erasmus MC Cancer Institute in the study 
period and were consequently scored for HGP. In total 1625 
CRLM were resected. Of these, 835 CRLM had two or 
more H&E stained slides available for review (2135 slides 
in total) and were considered for within metastasis analysis. 
Of these, 31 slides of ten individual CRLM were identi-
fied as consecutively cut from single FFPE blocks, and were 
hence excluded from within metastasis analysis. Resection 
of two or more CRLM was performed in 382 patients. Nine-
teen were excluded for between metastasis analysis due to 
missing data required to link individual tissue samples to 
individual CRLM. Within the remaining 363 patients a total 
of 1118 CRLM were resected. Patient characteristics are 
reported in Table 1.
Within metastasis concordance
Non-dHGP was observed in 72% of reviewed tissue blocks. 
Results of the multivariable logistic regression model on 
Table 1  Characteristics of patients included for between metastasis 
concordance analysis. CRLM colorectal liver metastasis, IQR inter-
quartile range, CEA carcinoembryonic antigen, CTx chemotherapy, 
RFA radiofrequency ablation, MWA microwave ablation, (non-)dHGP 
(non-)desmoplastic type histopathological growth pattern
n = 363 (%)
Gender
 Female 233 (64)
 Male 130 (36)
Age at resection CRLM—[median (IQR)] 63.0 (57.0–70.0)
Primary tumour location
 Right-sided 61 (17)
 Left-sided 152 (42)
 Rectal 145 (40)
 Missing 5 (1)
T-stage
 pT 0–2 70 (19)
 pT 3–4 265 (73)
 Missing 28 (8)
N-stage
 N0 118 (33)
 N+ 216 (60)
 Missing 29 (8)
Disease-free interval—months [median (IQR)] 0.0 [0.0–9.0]
Diameter of largest CRLM—cm [median (IQR)] 3.1 [2.0–4.8]
Preoperative CEA—µg/L [median (IQR)] 20.0 [5.4–70.1]
Preoperative CTx status
 Chemo-naive 121 (33)
 Pre-treated 242 (67)
Two-staged resection
 No 347 (96)
 Yes 16 (4)
Use of RFA or MWA
 No 252 (69)
 Yes 111 (31)
Number of CRLM resected
 2 175 (48)
 3 87 (24)
 4 58 (16)
 ≥ 5 43 (12)
Histopathological growth pattern
 dHGP 72 (20)
 Non-dHGP 291 (80)
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within metastasis discordance are reported in Table 2. Sys-
temic treatment status proved to be a significant predictor 
for presence of HGP discordance (yes/no) amongst multiple 
blocks, with an odds ratio (OR) (95% CI) of 2.107 (1.231; 
3.679) and p = 0.007 for pre-treated versus chemo-naive 
CRLM. Mean within metastasis concordance was 95%. 
Figure 2a shows the mean within metastasis concordance 
stratified by number of blocks scored. Mean within metas-
tasis concordance (95% CI) for 2, 3, 4, or ≥ 5 blocks scored 
was 96% (95; 97), 94% (92; 96), 93% (88; 98) and 94% (86; 
100) respectively and was independent of the number of 
blocks scored (p = 0.315).
Between metastasis concordance
Mean between metastasis concordance of all 363 patients 
was 90%. Since systemic treatment status was a signifi-
cant predictor for within metastasis discordance, between 
metastasis analysis was performed in chemo-naive and pre-
treated patients separately. Non-dHGP was found in 85% 
of chemo-naive patients versus 78% in pre-treated patients 
(p = 0.094). Results of the fitted multivariable logis-
tic regression models on presence of HGP discordance 
(yes/no) amongst multiple resected CRLM are reported 
in Table 2. Within chemo-naive patients, the size of the 
largest hepatic tumour on preoperative imaging proved a 
significant predictor for between metastasis discordance 
with OR (95% CI) 1.461 (1.073; 2.145) and p = 0.028 for 
every cm increase in size. The only significant predictor 
found for between metastasis discordance in pre-treated 
patients was number of CRLM resected. Corresponding 
OR (95% CI) were 3.602 (1.414–9.550) for 3 versus 2 
CRLM resected and 5.887 (2.585; 14.356) for ≥ 4 versus 2 
CRLM resected (p = 0.008 and p < 0.001). Mean between 
metastasis concordance (Fig. 2b) was significantly lower 
in pre-treated versus chemo-naive patients (88% vs. 94%, 
p = 0.006). Figure 2b shows the mean between metasta-
sis concordance for chemo-naive and pre-treated patients 
stratified by number of CRLM resected. In chemo-naive 
patients, mean between metastasis concordance [95% 
CI] did not differ amongst 2 (94% [91; 98]), 3 (94% [88; 
99]) or ≥ 4 (90% [78; 100]) CRLM resected (p = 0.678). 
In pre-treated patients mean between metastasis concord-
ance [95% CI] was significantly different amongst 2 (93% 
[90; 96]), 3 (85% [78; 92]) and ≥ 4 (83% [77; 88]) CRLM 
resected (p = 0.004).
Table 2  Multivariable binary logistic regression models on discordance (yes/no) in histopathological growth pattern
OR odds ratio, CI confidence interval, CRLM colorectal liver metastases, CEA carcinoembryonic antigen
a Continuous data entered into the model
b Omitted from within metastasis analysis since it is not representative for individual metastasis
c Used as stratification factor for between metastasis analysis
*α < 0.05
Variable Within metastasis (n = 702) Between metastasis (n = 308)
OR (95% CI) p-Value Chemo-naive (n = 111) Pre-treated (n = 197)
OR (95% CI) p-Value OR (95% CI) p-Value
Location of primary
 Left versus right 1.513 (0.721–3.487) 0.298 0.610 (0.086–5.237) 0.620 0.655 (0.261–1.660) 0.367
 Rectal versus right 1.881 (0.881–4.403) 0.120 3.174 (0.673–23.785) 0.186 0.604 (0.221–1.660) 0.324
pT3-4 versus pT0-2 1.259 (0.652–2.551) 0.506 1.163 (0.258–6.011) 0.848 1.193 (0.462–3.265) 0.721
Node-positive primary 0.650 (0.385–1.101) 0.107 0.516 (0.122–2.134) 0.354 0.696 (0.334–1.455) 0.332
Disease-free interval (months)a 0.998 (0.980–1.014) 0.852 0.995 (0.947–1.034) 0.828 1.017 (0.972–1.062) 0.434
Diameter of largest CRLM (cm)a,b – – 1.461 (1.073–2.145) 0.028* 1.139 (0.983–1.321) 0.081
Preoperative CEA (µg/L)a 0.999 (0.996–1.000) 0.152 0.996 (0.985–1.001) 0.278 1.000 (0.999–1.001) 0.575
Pre-treated versus  chemonaivec 2.107 (1.231–3.679) 0.007* – – – –
Number of blocks scored
 3 versus 2 1.994 (1.140–3.441) 0.014* – – – –
 4 versus 2 2.076 (0.788–4.869) 0.111 – – – –
 ≥ 5 versus 2 1.418 (0.322–4.411) 0.589 – – – –
Number of CRLM resected
 3 versus 2 – – 0.868 (0.188–3.443) 0.846 3.602 (1.414–9.550) 0.008*
 ≥ 4 versus 2 – – 1.617 (0.292–7.394) 0.548 5.887 (2.585–14.356) < 0.001*
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External validation
The external cohort comprised of 276 patients of whom the 
HGP could be determined in 251 (91%). In total 168 patients 
had resection performed of two or more CRLM and could be 
included for between metastasis analysis. Within metastasis 
analysis was performed in 270 CRLM with two or more 
blocks. Baseline characteristics were comparable between 
the external validation cohort and chemo-naive patients 
within the original cohort (Supplementary Table 1). Mean 
within (96% vs. 97%, p = 0.652) and between (94% vs. 94%, 
p = 0.710) metastasis concordance did not differ between the 
original (chemo-naive patients only) and validation cohort 
(Fig. 3).
Diagnostic accuracy
Supplementary Fig. 1a displays the AUC for scoring a single 
(95.9%), two (97.7%) or three blocks (98.8%) per metastasis. 
A significant increase in diagnostic accuracy was observed 
for scoring 2 versus 1 block(s) (p = 0.039), but not for scor-
ing 3 versus 2 blocks (p = 0.341). The AUC for scoring a sin-
gle (93.3%), two (96.5%) or three (98.2%) resected CRLM 
per patient are reported in Supplementary Fig. 1b. A signifi-
cant increase in diagnostic accuracy was found for scoring 
2 versus 1 resected CRLM (p = 0.026), but not for scoring 3 
versus 2 resected CRLM (p = 0.235).
Learning curve
The results of both test-sets as scored by the gold stand-
ard, the pathologist and the PhD candidate are graphically 
displayed in Fig. 4a–f. Interobserver agreement was higher 
in the second test-set for both the pathologist (k = 0.953 vs. 
k = 0.836) and the PhD candidate (k = 0.951 vs. k = 0.747). 
Where in the first test-set a difference in performance 
was seen between the pathologist and the PhD candidate 
(k = 0.836 and k = 0.747), performance in the second test-
set did not differ (k = 0.953 and k = 0.951).
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Fig. 2  a Within metastasis histopathological growth pattern (HGP) 
concordance within the original cohort stratified by number of blocks 
scored. Overall mean within metastasis concordance (μ) was 95%. 
b Mean between metastasis HGP concordance within the original 
cohort stratified by preoperative chemotherapy status and number of 
colorectal liver metastasis (CRLM) resected. Mean between metasta-
sis concordance in chemo-naive (CTx-) patients was 94% (μ1). Mean 
between metastasis concordance in pre-treated (CTx +) patients was 
88% (μ2). Error-bars represent the 95% confidence interval of the esti-
mate
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Fig. 3  External validation of within and between colorectal liver 
metastasis (CRLM) concordance of histopathological growth pattern. 
Comparison was performed between the external validation cohort 
and (tissue of) chemonaive subjects from the original cohort
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Discussion
The current study found within metastasis concordance to 
be high (95%) when classifying the HGP as dHGP or non-
dHGP. Furthermore, mean within metastasis concordance 
was independent of number of FFPE blocks scored. Overall 
between metastasis concordance was also high (90%), but 
differed for chemo-naive versus pre-treated patients (94% 
vs. 88%). In chemo-naive patients, mean between metastasis 
concordance was independent of number of CRLM resected 
and the only predictor found in multivariable analysis for 
discordance was size of largest hepatic tumour on preopera-
tive imaging. For pre-treated patients, the number of CRLM 
resected proved predictive for between metastasis discord-
ance. This finding was supported by a significant difference 
in mean concordance for 2, 3 or ≥ 4 resected CRLM within 
pre-treated patients.
External validation in a large cohort of chemo-naive 
patients found similarly high numbers of mean within (97%) 
and between (94%) metastasis concordance. Unfortunately, 
the external validation cohort comprised of chemo-naive 
patients only, as such external validation within pre-treated 
CRLM and patients could not be performed.
The current study suggests that systemic chemotherapy 
treatment prior to hepatic resection might somewhat affect 
the reliability of HGP assessment. In the same patient cohort 
as currently described, Galjart et al. reported a significant 
increase in dHGP within pre-treated patients [15]. It is as of 
yet unclear if this difference is due to chemotherapy directly 
changing HGP morphology, or due to selection bias in that 
patients with dHGP have improved prognosis and are thus 
more likely to complete their pre-operative chemotherapy 
and subsequent liver resection. Although inconclusive, the 
current study did find a higher heterogeneity amongst the 
HGP of slides and CRLM of pre-treated patients. This could 
be the result of chemotherapy having a direct effect on HGP 
morphology.
Two studies have previously reported on HGP concord-
ance so far. Van Dam et al. analysed within metastasis agree-
ment of ≥ 4 sections in a small sample of 50 CRLM [14] and 
Eefsen et al. reported on between metastases agreement in 
a small group of 24 patients with multiple resected CRLM 
[17]. As both studies applied different cut-off values to deter-
mine the HGP (50% and 75% respectively), interpretation of 
its results in light of the current study is difficult. Consider-
ing recent developments, it seems logical that future HGP 
classification will be based on the dHGP/non-dHGP cut-off.
When determining the diagnostic accuracy of HGP 
assessment, the current study found high AUC values for 
scoring a single, two or three blocks (all > 95%) or CRLM 
(all > 92%). The currently obtained results show that scor-
ing two instead of one FFPE block(s) per CRLM increased 
diagnostic accuracy significantly. This increase was not 
significant when scoring three versus two blocks. As such, 
scoring two blocks per CRLM seems preferable and little 
accuracy is gained by further increasing the number of 
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Fig. 4  a, d Results of the first and second test-set as scored by the 
experienced trainer (gold standard). b, e Results of the first and sec-
ond test-set as scored by the pathologist. c, f Results of the first and 
second test-set as scored by the PhD candidate. rHGP replacement 
type histopathological growth pattern (HGP), pHGP pushing type 
HGP, dHGP desmoplastic type HGP
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blocks assessed. This could significantly decrease work-
load, especially considering when non-dHGP is observed 
in a single block, the other available blocks of the same 
or different CRLM do not necessarily have to be assessed, 
for non-dHGP has readily been determined. Similar 
results were seen when looking at the diagnostic accuracy 
for scoring two versus one and three versus two CRLM 
resected in patients with multiple metastases. These 
findings suggest that CRLM treated by other modalities 
(e.g. ablative techniques) can accurately be diagnosed by 
CRLM resected within the same timeframe, especially in 
the case of two or more resected metastases.
Analysis of the learning curve showed that after a single 
training session by an experienced trainer good to excellent 
(k > 0.7) interobserver agreement for dHGP/non-dHGP was 
reached by two unexperienced observers. As expected, an 
observer with prior experience in liver pathology had a supe-
rior initial performance. After two training sessions how-
ever, the interobserver agreement was near perfect (k > 0.9) 
for both raters. Although only two unexperienced raters were 
included, these results suggest that HGP classification into 
dHGP or non-dHGP can be taught with relative ease and 
that interobserver agreement is high. In comparison, Chetty 
et al. reported on the interobserver agreement of tumour 
regression grade (TRG), a histopathological assessment 
within the field of colorectal cancer [27]. The overall agree-
ment (expressed in k) was determined for three separate 
scoring systems: the Mandard [28], Dworak [29] and the 
modified rectal cancer regression grading system (m-RCRG) 
[30]. Seventeen experienced rectal cancer pathologists were 
asked to score ten slides of ten separate cases of rectal can-
cer treated with long-course preoperative chemoradiation. 
Reported overall agreement for the Mandard, Dworak and 
m-RCRG were k = 0.28, k = 0.35 and k = 0.38, respectively 
[27]. Furthermore, these results are also promising for auto-
mated HGP determination using digital image slides and 
‘pathomics’, as it has shown great promise in other histologi-
cal phenotypes [31]. Especially considering the new on/off 
phenomenon as described by Galjart et al. [15], automated 
determination on digital sections is something worth inves-
tigating and the authors feel could be feasible.
Common biomarkers used in clinical practice for the 
treatment of colorectal cancer include K-RAS and B-RAF 
mutational status. Richman et al. reported on within tumour 
heterogeneity of K-RAS and B-RAF in 69 primary CRC 
cases [32]. Intra-tumoural heterogeneity was found in 5/69 
(7.2%) for K-RAS and 2/69 (2.9%) for B-RAF status [32]. 
When comparing multiple tumour sites, a recent meta-
analysis by Bhullar et al. reported on the concordance of, 
amongst others, K-RAS and B-RAF between the primary 
tumour and its corresponding metastases [33]. Median bio-
marker concordance [range] for K-RAS and B-RAF were 
93.7% [67–100] and 99.4% [80–100], respectively [33].
It appears that little within and between metastasis het-
erogeneity exists in the HGP of CRLM when classified as 
dHGP and non-dHGP. In addition, the observed heterogene-
ity seems comparable to that observed for biomarkers cur-
rently used in clinical practice. Furthermore, the diagnos-
tic accuracy and learnability of HGP assessment by light 
microscopy seems high. These findings suggest that the 
HGPs of CRLM are a reliable and replicable histological 
biomarker.
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tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
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